ANI Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
ANI Pharmaceuticals, Inc.‘s stocks are currently a part of 96 hedge funds’ portfolios, which represents 45.28% of the total amount of its stocks outstanding. This makes up a total of 7.36M shares of ANI Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -28.16% or -2.88M shares fewer. As for the holding position changes, 23.96% (23) of current hedge fund investors increased the number of shares held, 37.5% (36) of current holders sold a part of the shares held, and 6.25% (6) closed the holdings completely. 14 hedge funds are new holders of ANI Pharmaceuticals, Inc. stock in Q1 2023, it is 14.58% of total holders.
Hedge funds holding ANI Pharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 180 |
|---|---|
| Q3 2018 | 167 |
| Q4 2018 | 162 |
| Q1 2019 | 184 |
| Q2 2019 | 192 |
| Q3 2019 | 185 |
| Q4 2019 | 162 |
| Q1 2020 | 136 |
| Q2 2020 | 126 |
| Q3 2020 | 108 |
| Q4 2020 | 112 |
| Q1 2021 | 103 |
| Q2 2021 | 108 |
| Q3 2021 | 107 |
| Q4 2021 | 125 |
| Q1 2022 | 115 |
| Q2 2022 | 110 |
| Q3 2022 | 117 |
| Q4 2022 | 123 |
| Q1 2023 | 96 |
Hedge funds changes in ANI Pharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 28 | 71 | 43 | 18 | 20 |
|---|---|---|---|---|---|
| Q3 2018 | 19 | 67 | 53 | 30 | -2 |
| Q4 2018 | 17 | 55 | 64 | 21 | 5 |
| Q1 2019 | 37 | 58 | 54 | 15 | 20 |
| Q2 2019 | 22 | 80 | 52 | 12 | 26 |
| Q3 2019 | 18 | 71 | 64 | 24 | 8 |
| Q4 2019 | 14 | 64 | 58 | 31 | -5 |
| Q1 2020 | 14 | 47 | 54 | 37 | -16 |
| Q2 2020 | 17 | 41 | 43 | 27 | -2 |
| Q3 2020 | 12 | 42 | 36 | 30 | -12 |
| Q4 2020 | 18 | 38 | 42 | 15 | -1 |
| Q1 2021 | 12 | 28 | 46 | 20 | -3 |
| Q2 2021 | 13 | 37 | 39 | 8 | 11 |
| Q3 2021 | 12 | 27 | 46 | 12 | 10 |
| Q4 2021 | 35 | 46 | 28 | 16 | 0 |
| Q1 2022 | 14 | 52 | 39 | 23 | -13 |
| Q2 2022 | 12 | 50 | 30 | 14 | 4 |
| Q3 2022 | 15 | 32 | 49 | 8 | 13 |
| Q4 2022 | 22 | 46 | 33 | 15 | 7 |
| Q1 2023 | 14 | 23 | 36 | 6 | 17 |
Hedge funds changes in ANI Pharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 8,126,000 | 3,258,000 |
|---|---|---|
| Q3 2018 | 2,934,000 | 2,296,000 |
| Q4 2018 | 1,553,000 | 1,113,000 |
| Q1 2019 | 6,857,000 | 3,258,000 |
| Q2 2019 | 7,062,000 | 6,065,000 |
| Q3 2019 | 4,697,000 | 6,333,000 |
| Q4 2019 | 3,626,000 | 2,596,000 |
| Q1 2020 | 3,426,000 | 1,252,000 |
| Q2 2020 | 2,017,000 | 2,079,000 |
| Q3 2020 | 2,138,000 | 852,000 |
| Q4 2020 | 1,107,000 | 784,000 |
| Q1 2021 | 415,000 | 400,000 |
| Q2 2021 | 245,000 | 806,000 |
| Q3 2021 | 560,000 | 1,014,000 |
| Q4 2021 | 2,299,000 | 3,571,000 |
| Q1 2022 | 707,000 | 2,086,000 |
| Q2 2022 | 614,000 | 1,859,000 |
| Q3 2022 | 726,000 | 1,716,000 |
| Q4 2022 | 904,922 | 687,795 |
| Q1 2023 | 15,907,000 | 79,443,000 |